US20030176365A1 - Nutritional supplement for cerebral metabolic insufficiencies - Google Patents

Nutritional supplement for cerebral metabolic insufficiencies Download PDF

Info

Publication number
US20030176365A1
US20030176365A1 US10/379,816 US37981603A US2003176365A1 US 20030176365 A1 US20030176365 A1 US 20030176365A1 US 37981603 A US37981603 A US 37981603A US 2003176365 A1 US2003176365 A1 US 2003176365A1
Authority
US
United States
Prior art keywords
acid
pharmaceutical composition
group
mixtures
krebs cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/379,816
Inventor
John Blass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/379,816 priority Critical patent/US20030176365A1/en
Publication of US20030176365A1 publication Critical patent/US20030176365A1/en
Priority to US11/478,195 priority patent/US8338382B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to nutritional supplements for individuals suffering from cerebral metabolic insufficiencies and methods of treating disorders indicated by cerebral metabolic insufficiencies.
  • ATP adenosine triphosphate
  • ADP adenosine diphosphate
  • the process of catabolism involves the breakdown of proteins, polysaccharides, and lipids. Proteins are broken into smaller peptides and constituent amino acids, polysaccharides and disaccharides are broken down into their monosaccharide constituents, and lipids are broken down into glycerol and the fatty acid constituents. These compounds are further broken down into even smaller compounds, principally, two-carbon acetyl groups.
  • the two-carbon acetyl group is introduced into the Krebs tricarboxylic acid cycle (“Krebs cycle”) via acetyl coenzyme A.
  • the acetyl group serves as a carbon source for the final stages of catabolism.
  • the Krebs cycle and an accompanying electron transport system involve a series of enzymatically controlled reactions which enable complete oxidation of the two-carbon acetyl group to form carbon dioxide and water.
  • acetyl groups are introduced into the Krebs cycle by bonding to oxaloacetic acid to form citric acid.
  • citric acid is converted into aconitic acid and then isocitric acid or, alternatively, it is converted directly into isocitric acid.
  • isocitric acid is converted into ketoglutaric acid, one carbon atom is completely oxidized to carbon dioxide.
  • ketoglutaric acid is converted into succinic acid, a second carbon atom is completely oxidized to carbon dioxide.
  • succinic acid is converted into fumaric acid, fumaric acid is converted into malic acid, and malic acid is converted into oxaloacetic acid.
  • Each complete turn of the Krebs cycle harvests the energy of the acetyl group to yield one molecule of ATP, three molecules of nicotinamide adenine dinucleotide (“NADH”), and one molecule of flavin adenine dinucleotide FADH 2 .
  • NADH nicotinamide adenine dinucleotide
  • FADH 2 flavin adenine dinucleotide
  • the Krebs cycle and the accompanying electron transport system occur in the mitochondria, which are present in different types of cells in varying numbers depending upon the cellular energy requirements.
  • neuronal and muscle cells have high numbers of mitochondria because they have extremely high energy requirements.
  • these types of cells are particularly vulnerable to disorders or conditions associated with a breakdown of the catabolic pathways or otherwise defective intracellular energy metabolism.
  • disorders or conditions include Alzheimer's Disease (“AD”), Parkinson's Disease (“PD”), Huntington's Disease (“HD”), and other neurodegenerative disorders (Beal et al., “Do Defects in Mitochondrial Energy Metabolism Underlie the Pathology of Neurodegenerative Diseases?,” Trends Neurosci.
  • AD Alzheimer's Association
  • AD is one of the most common causes of disabling dementia in humans. Because AD is a progressive, degenerative illness, it affects not only the patient, but also their families and caregivers. In early stages of AD, activities of daily living (“ADLs”) are only minimally affected by cognitive or functional impairment, which may often be a first clinical sign of the disease (Small et al., “Diagnosis and Treatment of Alzheimer Disease and Related Disorders,” Consensus Statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society, JAMA 278:1363-1371 (1997)).
  • ADLs activities of daily living
  • PD is widely considered to be the result of degradation of the pre-synaptic dopaminergic neurons in the brain, with a subsequent decrease in the amount of the neurotransmitter dopamine that is being released. Inadequate dopamine release, therefore, leads to the onset of voluntary muscle control disturbances symptomatic of PD.
  • the motor dysfunction symptoms of PD have been treated in the past using dopamine receptor agonists, monoamine oxidase binding inhibitors, tricyclic antidepressants, anticholinergics, and histamine H1-antagonists. Unfortunately, the main pathologic event, degeneration of the cells in substantia nigra, is not helped by such treatments.
  • PD neuropsychiatric disorders or symptoms. These include apathy-amotivation, depression, and dementia. PD patients with dementia have been reported to respond less well to standard L-dopa therapy. Moreover, these treatments have little or no benefit with respect to the neuropsychiatric symptoms.
  • HD is a familial neurodegenerative disorder that afflicts about ⁇ fraction (1/10,000) ⁇ individuals (Martin et al., “Huntington's Disease: Pathogenesis and Management,” N. Engl. J. Med. 315:1267-1276 (1986); Gusella, “Huntington's Disease,” Adv. Hum. Genet. 20:125-151 (1991)). It is inherited in an autosomal dominant manner and is characterized by choreiform movements, dementia, and cognitive decline. The disorder usually has a mid-life onset, between the ages of 30 to 50 years, but may in some cases begin very early or much later in life.
  • the symptoms are progressive and death typically ensues 10 to 20 years after onset, most often as the result of secondary complications of the movement disorder.
  • the major site of pathology in HD is the striatum, where up to 90% of the neurons may be depleted.
  • the impaired cognitive functions and eventual dementia may be due either to the loss of cortical neurons or to the disruption of normal activity in the cognitive portions of the basal ganglia.
  • the characteristic chorea is believed to be caused by the neuronal loss in the striatum, although a reduction in subthalamic nucleus activity may also contribute.
  • Glutamate-induced neuronal cell death is believed to contribute to HD.
  • Glutamate is the principal excitatory transmitter in the brain. It excites virtually all central neurons and is present in the nerve terminals in extremely high concentrations (10 31 3 M).
  • Glutamate receptors are divided into four types (named after their model agonists): kainate receptors, N-methyl-D-aspartate (“NMDA”) receptors, ⁇ -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (“AMPA”) receptors, and metabolotrophic receptors. Many normal synaptic transmission events involve glutamate release.
  • glutamate can also induce neurotoxicity and neuronal death at high levels (Choi, “Glutamate Neurotoxicity and Diseases of the Nervous System,” Neuron, 1:623-634 (1988)).
  • the mechanism of cell death occurs primarily by the persistent action of glutamate on the NMDA receptors.
  • glutamate excitotoxicity are believed to be the cause of cell damage and death after acute brain injury such as stroke or excessive convulsions.
  • Izumi the administration of pyruvate to a patient before or after an ischemic event (i.e., which produces a state of hypoxia or hypoglycemia) is sufficient to prevent neuronal degradation that normally is associated with the ischemic event. Izumi also identified the administration of glucose prior to an ischemic event as undesirable, because its administration resulted in lactic acidosis, which is a factor contributing to brain damage.
  • An approach for the treatment of AD includes the administration of NADH or nicotinamide adenine dinucleotide phosphate (“NADPH”), or the salts thereof.
  • NADH or NADPH is described in U.S. Pat. No. 5,444,053 to Birkmayer, which discloses the use of salts formed with various acids including, among others, malic acid, succinic acid, and acetic acid.
  • Similar approaches to treating PD using NADH and NADPH are described in U.S. Pat. Nos. 5,019,561 and 4,970,200, both to Birkmayer.
  • the present invention is directed toward overcoming these above-noted deficiencies in treating conditions associated with a breakdown of the catabolic pathways or otherwise defective intracellular energy metabolism.
  • the present invention relates to a pharmaceutical composition which includes a sugar and a Krebs cycle intermediate or salt thereof, or a precursor of a Krebs cycle intermediate.
  • Krebs cycle intermediates include citric acid, aconitic acid, isocitric acid, ⁇ -ketoglutaric, succinic acid, fumaric acid, malic acid, oxaloacetic acid, and mixtures thereof.
  • Precursors of Krebs cycle intermediates are compounds which, upon administration to a subject, are converted by the body to form a Krebs cycle intermediate.
  • the present invention also relates to a method of treating impaired mitochondrial function.
  • the method includes administering a pharmaceutical composition of the present invention to a subject having a disorder involving impaired mitochondrial function under conditions effective to improve mitochondrial function.
  • the present invention further relates to a method of improving cerebral function in an individual having impaired cerebral metabolism.
  • This method includes administering a pharmaceutical composition of the present invention to a subject having impaired cerebral metabolism under conditions effective to improve cerebral function.
  • the pharmaceutical compositions of the present invention are particularly desirable for the prophylaxis or treatment of disorders associated with impaired mitochondrial function.
  • Disorders that can be treated include conditions or diseases characterized by a decreased level of oxidative metabolism, such as conditions or diseases of the nervous system, conditions or diseases of other parts of the body (e.g., cardiovascular disorders, musculoskeletal disorders, etc.), and conditions or diseases of the body as a whole.
  • the pharmaceutical composition is particularly desirable for use in treating nervous system disorders that are indicated by symptoms of dementia. Upon administration of the pharmaceutical compositions of the present invention, it is possible to reduce the severity of dementia through enhancing cerebral cellular metabolism (i.e., improving mitochondrial function in cerebellar tissues).
  • the pharmaceutical compositions are particularly useful as a prophylactic for delaying the onset of dementia or as a treatment for delaying the progression of dementia associated with various nervous system disorders.
  • the pharmaceutical compositions are also useful for ameliorating the clinical manifestations of dementing illnesses by improving the function of the remaining, but often metabolically compromised, cells.
  • FIG. 1 illustrates the Krebs cycle and the relationship between each of its intermediates.
  • Oxaloacetic acid and an acetyl group combine to form citric acid.
  • two of the carbon atoms of citric acid are oxidized completely to carbon dioxide, and oxaloacetic acid is regenerated. This process generates one molecule of ATP, three molecules of NADH, and one molecule of FADH 2 .
  • the reduced cofactors NADH and FADH 2 are introduced into an electron-transport mechanism that results in their oxidation, which yields additional molecules of ATP.
  • the present invention relates to a pharmaceutical composition which includes a sugar in combination with a Krebs cycle intermediate or a precursor of a Krebs cycle intermediate.
  • Krebs cycle intermediates are the acids or salts of compounds which are utilized during the Krebs cycle.
  • Krebs cycle intermediates include citric acid, aconitic acid, isocitric acid, ⁇ -ketoglutaric acid, succinic acid, fumaric acid, malic acid, oxaloacetic acid, or mixtures thereof.
  • the pharmaceutical composition of the present invention will be predicted ultimately to yield differing amounts of ATP. It is believed that a number of disorders involving altered oxidative metabolism include a disruption of the Krebs cycle at or prior to conversion of ⁇ -ketoglutaric acid to succinic acid.
  • the pharmaceutic compositions of the present invention preferably contain a Krebs cycle intermediate such as succinic acid, fumaric acid, malic acid, oxaloacetic acid, or mixtures thereof.
  • Precursors of Krebs cycle intermediates are compounds which upon administration to a subject are converted by the body (i.e., in vivo) into a Krebs cycle intermediate.
  • a Krebs cycle intermediate Generally, mono- and di-alkyl citrates, aconitates, isocitrates, ⁇ -ketoglutarates, succinates, fumarates, malates, and oxaloacetates are desirable precursors because the ester bonds are readily broken by the body to yield the Krebs cycle intermediate.
  • Other ester precursors may be developed using known technology for enhancing entry of the precursor molecule into affected cells. For example, U.S. Pat. No.
  • 5,739,117 to Yokoyama discloses a variety of glucose ester derivatives which more effectively enter brain cells.
  • One preferred class of precursors of Krebs cycle intermediates are compounds which are converted by the body into oxaloacetic acid or oxaloacetate.
  • Exemplary precursors in this class include 2-keto-4-hydroxypropanol, 2,4-dihydroxybutanol, 2-keto-4-hydroxybutanol, 2,4-dihydroxybutyric acid, 2-keto-4-hydroxybutyric acid, aspartates, as well as the previously identified mono- and di-alkyl oxaloacetates.
  • the amino acid aspartate is converted into oxaloacetic acid by the transamination reaction.
  • Sugars which are suitable for use with the present invention include monosaccharides, such as glucose, fructose, mannose, and galactose; disaccharides such as sucrose, maltose, and lactose; and polysaccharides (i.e., starches such as amylose) that are digested by the body to form monosaccharides.
  • monosaccharides such as glucose, fructose, mannose, and galactose
  • disaccharides such as sucrose, maltose, and lactose
  • polysaccharides i.e., starches such as amylose
  • the pharmaceutical composition of the present invention can also include an adjuvant for enhancing mitochondrial function (i.e., oxidative metabolism).
  • Suitable adjuvants include vitamins, minerals, antioxidants, and other metabolism-enhancing compounds.
  • B-complex vitamins are preferred for administration as adjuvants because of their involvement with metabolism.
  • Exemplary vitamins which are useful as an adjuvant include thiamin (vitamin B 1 ), riboflavin (vitamin B 2 ), niacin (Vitamin B 3 ), pyridoxine derivatives (vitamin B 6 ), and pantothenic acid.
  • Exemplary minerals which are useful as an adjuvant include calcium, magnesium, sodium, potassium, and zinc.
  • Exemplary antioxidants include ascorbic acid, alpha-tocopherol, resveritrol, quercetin, and other flavonoids.
  • Exemplary metabolism-enhancing compounds include L-carnitine and its derivatives, and creatine. Creatine supplementation is described in U.S. Pat. No. 5,767,159 to Hultman, which is hereby incorporated by reference. L-camitine has been found to ameliorate abnormalities associated with AD in a model system (Malow et al., “Cultured Cells as a Screen for Novel Treatments of Alzheimer's Disease,” Arch. Neurol. 46:1201-1203 (1989), which is hereby incorporated by reference).
  • the pharmaceutical composition of the present invention can be administered orally, by anal suppository, parenterally, for example, subcutaneously, intravenously, intramuscularly, intraperitoneally, intrathecally, by interstitial infusion, by intranasal instillation, or by application to mucous membranes, such as that of the nose, throat, and bronchial tubes.
  • parenterally for example, subcutaneously, intravenously, intramuscularly, intraperitoneally, intrathecally, by interstitial infusion, by intranasal instillation, or by application to mucous membranes, such as that of the nose, throat, and bronchial tubes.
  • suitable pharmaceutically-acceptable vehicles can be in solid or liquid form such as tablets, capsules, powders, solutions, suspensions, or emulsions.
  • the solid unit dosage forms can be of the conventional type, such as an ordinary gelatin type containing the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate and a pharmaceutically acceptable vehicle.
  • Suitable vehicles include lubricants and inert fillers.
  • the above described sugars can also serve as fillers.
  • these compounds are tableted with conventional tablet bases (i.e., sugars as described above) in combination with binders like acacia, gum tragacanth, cornstarch, or gelatin; disintegrating agents such as cornstarch, potato starch, or alginic acid; a lubricant like stearic acid or magnesium stearate; and sweetening agents such as the above described sugars, saccharine, or aspartame; and flavoring agents such as peppermint oil, oil of wintergreen, or artificial flavorings.
  • conventional tablet bases i.e., sugars as described above
  • binders like acacia, gum tragacanth, cornstarch, or gelatin
  • disintegrating agents such as cornstarch, potato starch, or alginic acid
  • a lubricant like stearic acid or magnesium stearate
  • sweetening agents such as the above described sugars, saccharine, or aspartame
  • flavoring agents such as peppermint oil, oil of wintergreen,
  • compositions of the present invention may also be administered in injectable dosages by solution or suspension of these materials in a physiologically acceptable diluent with a pharmaceutical vehicle.
  • a pharmaceutical vehicle include sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants such as those described above.
  • Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil.
  • water, saline, aqueous sugar solutions formed with the above-described sugars, and glycols such as polypropylene glycol or polyethylene glycol are preferred liquid vehicles, particularly for injectable solutions.
  • antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like may be added to the vehicle.
  • the pharmaceutical composition of the present invention is useful for augmenting cellular metabolism in subjects (e.g., patients) who suffer from a disorder characterized by abnormally decreased levels of oxidative metabolism. It is believed that administration of the pharmaceutical composition of the present invention enhances mitochondrial function by augmenting operation of the Krebs cycle.
  • Administering sugar to a subject provides a carbon source for producing acetyl groups and administering the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate to a subject increases the concentration of the particular Krebs cycle intermediate at the mitochondrial level. It is believed that this has a priming effect, because a four carbon intermediate is needed in order for the two-carbon derivatives of glucose and other substrates to enter the Krebs cycle.
  • the two-carbon acetyl group must combine with the four-carbon oxaloacetate to form citrate in order for the Krebs cycle to continue.
  • Malate is in equilibrium with oxaloacetate, and other Krebs cycle intermediates are readily converted to malate and oxaloacetate.
  • the conversion of succinate and fumarate to malate and oxaloacetate is particularly rapid.
  • Metabolically compromised cells tend to utilize Krebs cycle intermediates for the direct generation of energy. More specifically, they utilize the intermediates to generate electrons which then generate ATP through electron transport. While utilizing the intermediates provides an immediate source of energy, doing so compromises the subsequent activity of the Krebs cycle.
  • Administration of the pharmaceutical compositions of the present invention is believed, therefore, to prime the Krebs cycle so that it again operates efficiently.
  • another aspect of the present invention relates to a method of treating a subject having a disorder involving impaired mitochondrial function.
  • the method includes administering the pharmaceutical composition of the present invention to a subject under conditions effective to improve mitochondrial function.
  • This method of the present invention is particularly useful for the treatment or prophylaxis of disorders associated with impaired mitochondrial function.
  • Disorders that can be treated according to this method generally include conditions or diseases characterized by a decreased level of oxidative metabolism.
  • the disorders may be caused by genetic factors, environmental factors, or both. More specifically, such disorders include conditions or diseases of the nervous system (e.g., neurodegenerative, psychoses, etc.), conditions or diseases of other parts of the body, and conditions or diseases of the body as a whole.
  • exemplary conditions or diseases of the nervous system include Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, spinocerebellar ataxias, and psychoses (including depression or schizophrenia) associated with oxidative metabolic abnormalities.
  • Exemplary conditions or disorders of other parts of the body include cardiovascular disorders (e.g., atherosclerotic and cardiovascular diseases including myocardial infarctions, angina, cardiomyopathies, cardiac valvular disorders, and other conditions or disorders causing cardiac failure), musculoskeletal disorders in which oxidative metabolism is abnormal (De Coo et al., A Mitochondrial tRNA(Val) Gene Mutation (G1642A) in a Patient With Mitochondrial Myopathy, Lactic Acidosis, and Stroke-like Episodes,” Neurol.
  • cardiovascular disorders e.g., atherosclerotic and cardiovascular diseases including myocardial infarctions, angina, cardiomyopathies, cardiac valvular disorders, and other conditions or disorders causing cardiac failure
  • musculoskeletal disorders in which oxidative metabolism is abnormal (De Coo et al., A Mitochondrial tRNA(Val) Gene Mutation (G1642A) in a Patient With Mitochondrial Myopathy
  • a pharmaceutical composition of the present invention is administered to a subject having impaired cerebral metabolism under conditions effective to improve the cerebral cellular metabolism. By improving cerebral cellular metabolism, the subject's cerebral function is improved significantly.
  • Treatment for nervous system disorders typically involves administration of the pharmaceutical composition of the present invention so that the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate is introduced into brain tissue.
  • the sugar and the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate must be transported into the brain cells and subsequently the Krebs cycle intermediate and derivatives of the sugar (e.g., pyruvate, acetate) must be incorporated into the brain cell mitochondria (i.e., where they may be incorporated into the Krebs cycle).
  • BBB cerebrovascular endothelium
  • the BBB is formed by cerebral endothelial cells under the influence of astroglial cells of the brain (Johansson, “Experimental Models of Altering the Blood Brain Barrier,” Progress in Brain Research, 91:171-175 (1992); Ermisch, “Peptide Receptors of the Blood-Brain Barrier and Substrate Transport into the Brain,” Progress in Brain Research 91:155-161 (1992), which are hereby incorporated by reference).
  • the BBB contains a monolayer of tightly connected microvascular endothelial cells with anionic charges. This layer separates two fluid-containing compartments: the blood plasma and extracellular fluid of the brain parenchyma.
  • One of the main functions of the BBB is to regulate the transfer of components between blood plasma and extracellular fluid.
  • the BBB limits free passage of molecules from the blood to the brain cells. This limited penetration into the CNS is noticeable with large molecules of high polarity such as protein conjugates, enzymes, etc. (Bobo et al., “Convection-enhanced Delivery of Macromolecules in the Brain,” Proc. Natl. Acad. Sci. USA, 91:2076-2080 (1994), which is hereby incorporated by reference).
  • the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate is administered in a form which more readily crosses the BBB and enters individual brain cells.
  • mono- or di-alkyl esters of Krebs cycle intermediates e.g., malate esters
  • the ester precursors are more lipophilic and, therefore, more likely to cross the BBB. See U.S. Pat. No. 5,739,117 to Yokoyama, which is hereby incorporated by reference.
  • the BBB is circumvented according to any of a variety of known strategies, for example, intrathecal injections (Ommaya, “Implantable Devices for Chronic Access and Drug Delivery to the Central Nervous System,” Cancer Drug Delivery, 1(2): 169-179 (1984), which is hereby incorporated by reference), surgical implants (U.S. Pat. No. 5,222,982 to Ommaya, which is hereby incorporated by reference), and interstitial infusion (Bobo et al., “Convection-enhanced Delivery of Macromolecules in the Brain,” Proc. Natl. Acad. Sci. USA, 91:2076-2080 (1994), which is hereby incorporated by reference).
  • Each of these strategies involve delivery of the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate to the central nervous system by direct administration into the cerebrospinal fluid or into the brain parenchyma.
  • the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate is linked to a molecule which enhances crossing of the BBB.
  • BBB crossing enhancers e.g., permeabilizer peptides
  • others are constantly being identified.
  • the pharmaceutical composition of the present invention is useful for treating a subject having a nervous system disorder which involves impaired mitochondrial function.
  • nervous system disorders are known to involve deficiencies in neurotransmitter systems.
  • AD is associated with degeneration of cholinergic neurons in the basal forebrain that play a fundamental role in cognitive functions, including memory (Becker et al., “Mechanisms of Cholinesterase Inhibition in Senile Dementia of the Alzheimer Type: Clinical, Pharmacological, and Therapeutic Aspects,” Drug Dev. Res. 12: 163-195 (1988)).
  • AD Alzheimer's disease
  • NMDA glutamate receptor antagonists may be of clinical benefit for patients having these disorders (Woodruff et al., “The Interaction Between MK-801 and Receptors for N-methyl-D-aspartate: Functional Consequences,” Neuropharm. 26:903-909 (1987); Greenamyre et al., “N-methyl-D-aspartate Antagonists in the Treatment of Parkinson's Disease,” Arch. Neurol.
  • the pharmaceutical composition of the present invention can be administered alone or in combination with a therapeutic agent for the treatment of a nervous system disorder.
  • suitable therapeutic agents include conventional medications for treating such nervous system disorders.
  • the pharmaceutical composition can be administered in combination with either an acetylcholinesterase inhibitor, an acetylcholine synthesis, storage or release modulator, an NDMA glutamate receptor antagonist, or combinations thereof.
  • an acetylcholinesterase inhibitor an acetylcholine synthesis, storage or release modulator
  • an NDMA glutamate receptor antagonist or combinations thereof.
  • a number of suitable acetylcholinesterase inhibitors, acetylcholine synthesis, storage or release modulators, and NDMA glutamate receptor antagonists are currently known and others are continually being discovered and reported.
  • the pharmaceutical composition of the present invention is useful for treating a subject having a cardiovascular disorder which involves impaired mitochondrial function.
  • the pharmaceutical composition of the present invention can be administered alone or in combination with conventional agents for the treatment of cardiovascular disorders.
  • the pharmaceutical composition of the present invention can be administered simultaneously with either blood-thinners, cholesterol lowering agents, anti-platelet agents, vasodilators, beta-blockers, angiotensin blockers, digitalis and its derivatives, and combinations thereof.
  • blood-thinners, cholesterol lowering agents, anti-platelet agents, vasodilators, beta-blockers, angiotensin blockers, and digitalis derivatives are currently known and others are continually being discovered and reported.
  • the pharmaceutical composition of the present invention is useful for treating a subject having a musculoskeletal disorder which involves impaired mitochondrial function.
  • the pharmaceutical composition of the present invention can be administered alone or in combination with conventional agents for the treatment of musculoskeletal disorders.
  • Malic acid was administered to seven (7) patients with Alzheimer's Disease in an open study. The longest any patient received malic acid was sixteen weeks. Each of the patients received 15 grams of malic acid per day, which was administered by dissolving the malic acid in unsweetened grape juice, which naturally contains glucose. The addition of the malic acid to the unsweetened grape juice resulted in a sour tasting liquid.
  • MMSE Mini-Mental State Examination
  • the MMSE is divided into two sections. The first section requires only vocal responses and tests the patient's orientation, memory, and attention. The second section tests the patient's ability to name, follow verbal and written commands, write a sentence spontaneously, and copy a complex polygon. The maximum score on the first section is 21 and the maximum score on the second section is 9, for a maximum total score of 30. Higher scores on the MMSE indicate better performance. Scores of 28-30 indicate normal intelligence, scores of 23 or below indicate dementia, and scores of 9 or below indicate severe dementia.
  • a 60 year old man with a strong family history of depression was on maintenance therapy for recurrent depression with an SSRI (Prozac 40 mg/day). After two weeks on the pharmaceutical composition containing malic acid and glucose, the man felt more calm and less pressured. While taking the pharmaceutical composition, the Prozac was reduced to 20 mg/day without deterioration of function. After stopping administration of the pharmaceutical composition, he again required 40 mg/day Prozac.

Abstract

The present invention relates to a pharmaceutical composition which includes a sugar and a Krebs cycle intermediate, or salt thereof, or a precursor of a Krebs cycle intermediate. Krebs cycle intermediates include citric acid, aconitic acid, isocitric acid, α-ketoglutaric, succinic acid, fumaric acid, malic acid, and oxaloacetic acid, and mixtures thereof. Precursors of Krebs cycle intermediates are compounds converted by the body to form a Krebs cycle intermediate. The present invention also relates to administration of the pharmaceutical composition to treat an individual for a disorder involving impaired mitochondrial function and to improve cerebral function in an individual having impaired cerebral metabolism.

Description

  • This application is a continuation of U.S. patent application Ser. No. 09/529,091, which is a national stage application under 35 USC §371 of PCT Application PCT/US98/18120 filed Sep. 1, 1998, which claims the benefit of U.S. Provisional Patent Application No. 60/063,165, filed Oct. 24, 1997.[0001]
  • FIELD OF THE INVENTION
  • The present invention relates to nutritional supplements for individuals suffering from cerebral metabolic insufficiencies and methods of treating disorders indicated by cerebral metabolic insufficiencies. [0002]
  • BACKGROUND OF THE INVENTION
  • During normal operation of the catabolic process, energy is harvested and subsequently stored in a readily available form, namely, the phosphate bonds of adenosine triphosphate (“ATP”). When energy is required for anabolic processes, a phosphate bond of ATP is broken to yield energy for driving anabolic reactions and adenosine diphosphate (“ADP”) is regenerated. The process of catabolism involves the breakdown of proteins, polysaccharides, and lipids. Proteins are broken into smaller peptides and constituent amino acids, polysaccharides and disaccharides are broken down into their monosaccharide constituents, and lipids are broken down into glycerol and the fatty acid constituents. These compounds are further broken down into even smaller compounds, principally, two-carbon acetyl groups. [0003]
  • The two-carbon acetyl group, an essential component in the catabolic process, is introduced into the Krebs tricarboxylic acid cycle (“Krebs cycle”) via acetyl coenzyme A. The acetyl group serves as a carbon source for the final stages of catabolism. The Krebs cycle and an accompanying electron transport system involve a series of enzymatically controlled reactions which enable complete oxidation of the two-carbon acetyl group to form carbon dioxide and water. As shown in FIG. 1, acetyl groups are introduced into the Krebs cycle by bonding to oxaloacetic acid to form citric acid. During subsequent steps of the Krebs cycle, citric acid is converted into aconitic acid and then isocitric acid or, alternatively, it is converted directly into isocitric acid. As isocitric acid is converted into ketoglutaric acid, one carbon atom is completely oxidized to carbon dioxide. As ketoglutaric acid is converted into succinic acid, a second carbon atom is completely oxidized to carbon dioxide. During the remaining steps, succinic acid is converted into fumaric acid, fumaric acid is converted into malic acid, and malic acid is converted into oxaloacetic acid. Each complete turn of the Krebs cycle harvests the energy of the acetyl group to yield one molecule of ATP, three molecules of nicotinamide adenine dinucleotide (“NADH”), and one molecule of flavin adenine dinucleotide FADH[0004] 2. The NADH and FADH2 are subsequently used as electron donors in the electron transport system to yield additional molecules of ATP.
  • The Krebs cycle and the accompanying electron transport system occur in the mitochondria, which are present in different types of cells in varying numbers depending upon the cellular energy requirements. For example, neuronal and muscle cells have high numbers of mitochondria because they have extremely high energy requirements. Because of their high energy requirements, these types of cells are particularly vulnerable to disorders or conditions associated with a breakdown of the catabolic pathways or otherwise defective intracellular energy metabolism. Exemplary disorders or conditions include Alzheimer's Disease (“AD”), Parkinson's Disease (“PD”), Huntington's Disease (“HD”), and other neurodegenerative disorders (Beal et al., “Do Defects in Mitochondrial Energy Metabolism Underlie the Pathology of Neurodegenerative Diseases?,” [0005] Trends Neurosci. 16(4):125-131 (1993); Jenkins et al., “Evidence for Impairment of Energy Metabolism in vivo in Huntington's Disease Using Localized 1H NMR Spectroscopy,” Neurol. 43:2689-2695 (1993)).
  • AD is one of the most common causes of disabling dementia in humans. Because AD is a progressive, degenerative illness, it affects not only the patient, but also their families and caregivers. In early stages of AD, activities of daily living (“ADLs”) are only minimally affected by cognitive or functional impairment, which may often be a first clinical sign of the disease (Small et al., “Diagnosis and Treatment of Alzheimer Disease and Related Disorders,” Consensus Statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society, [0006] JAMA 278:1363-1371 (1997)). As AD progresses, the patients' ability to perform ADLs diminishes and they become increasingly more dependent upon caregivers and other family members (see Galasko et al., “An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease,” Alzheimer Dis. Assoc. Disord. 11(Suppl. 2):S33-S39 (1997)).
  • PD is widely considered to be the result of degradation of the pre-synaptic dopaminergic neurons in the brain, with a subsequent decrease in the amount of the neurotransmitter dopamine that is being released. Inadequate dopamine release, therefore, leads to the onset of voluntary muscle control disturbances symptomatic of PD. The motor dysfunction symptoms of PD have been treated in the past using dopamine receptor agonists, monoamine oxidase binding inhibitors, tricyclic antidepressants, anticholinergics, and histamine H1-antagonists. Unfortunately, the main pathologic event, degeneration of the cells in substantia nigra, is not helped by such treatments. The disease continues to progress and, frequently after a certain length of time, dopamine replacement treatment will lose its effectiveness. In addition to motor dysfunction, however, PD is also characterized by neuropsychiatric disorders or symptoms. These include apathy-amotivation, depression, and dementia. PD patients with dementia have been reported to respond less well to standard L-dopa therapy. Moreover, these treatments have little or no benefit with respect to the neuropsychiatric symptoms. [0007]
  • HD is a familial neurodegenerative disorder that afflicts about {fraction (1/10,000)} individuals (Martin et al., “Huntington's Disease: Pathogenesis and Management,” [0008] N. Engl. J. Med. 315:1267-1276 (1986); Gusella, “Huntington's Disease,” Adv. Hum. Genet. 20:125-151 (1991)). It is inherited in an autosomal dominant manner and is characterized by choreiform movements, dementia, and cognitive decline. The disorder usually has a mid-life onset, between the ages of 30 to 50 years, but may in some cases begin very early or much later in life. The symptoms are progressive and death typically ensues 10 to 20 years after onset, most often as the result of secondary complications of the movement disorder. The major site of pathology in HD is the striatum, where up to 90% of the neurons may be depleted. The impaired cognitive functions and eventual dementia may be due either to the loss of cortical neurons or to the disruption of normal activity in the cognitive portions of the basal ganglia. The characteristic chorea is believed to be caused by the neuronal loss in the striatum, although a reduction in subthalamic nucleus activity may also contribute.
  • Glutamate-induced neuronal cell death is believed to contribute to HD. Glutamate is the principal excitatory transmitter in the brain. It excites virtually all central neurons and is present in the nerve terminals in extremely high concentrations (10[0009] 31 3 M). Glutamate receptors are divided into four types (named after their model agonists): kainate receptors, N-methyl-D-aspartate (“NMDA”) receptors, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (“AMPA”) receptors, and metabolotrophic receptors. Many normal synaptic transmission events involve glutamate release. However, glutamate can also induce neurotoxicity and neuronal death at high levels (Choi, “Glutamate Neurotoxicity and Diseases of the Nervous System,” Neuron, 1:623-634 (1988)). The mechanism of cell death occurs primarily by the persistent action of glutamate on the NMDA receptors. These toxic changes produced by glutamate, called glutamate excitotoxicity, are believed to be the cause of cell damage and death after acute brain injury such as stroke or excessive convulsions. It has been suggested that excitotoxicity may be involved in brain ischemia, AD, and HD (Greenamyre et al., “Alterations in L-glutamate Binding in Alzheimer's and Huntington's Diseases,” Science, 227:1496-1499 (1985); Choi, “Glutamate Neurotoxicity and Diseases of the Nervous System,” Neuron, 1:623-634 (1988)).
  • The administration of agents that improve energy metabolism, and possibly prevent cell death, has been suggested for the treatment of disorders characterized by energy-deficient cells (Beal et al., “Do Defects in Mitochondrial Energy Metabolism Underlie the Pathology of Neurodegenerative Diseases?,” [0010] Trends Neurosci. 16(4):125-131 (1993)). One approach to augmenting the energy level of energy-deficient cells (i.e., as a result of hypoxia or hypoglycemia) involves the administration of pyruvate, which is later converted to acetate during normal metabolism. According to U.S. Pat. No. 5,395,822 to Izumi et al. (“Izumi”), the administration of pyruvate to a patient before or after an ischemic event (i.e., which produces a state of hypoxia or hypoglycemia) is sufficient to prevent neuronal degradation that normally is associated with the ischemic event. Izumi also identified the administration of glucose prior to an ischemic event as undesirable, because its administration resulted in lactic acidosis, which is a factor contributing to brain damage.
  • An approach for the treatment of AD includes the administration of NADH or nicotinamide adenine dinucleotide phosphate (“NADPH”), or the salts thereof. The administration of NADH or NADPH is described in U.S. Pat. No. 5,444,053 to Birkmayer, which discloses the use of salts formed with various acids including, among others, malic acid, succinic acid, and acetic acid. Similar approaches to treating PD using NADH and NADPH are described in U.S. Pat. Nos. 5,019,561 and 4,970,200, both to Birkmayer. [0011]
  • The present invention is directed toward overcoming these above-noted deficiencies in treating conditions associated with a breakdown of the catabolic pathways or otherwise defective intracellular energy metabolism. [0012]
  • SUMMARY OF THE INVENTION
  • The present invention relates to a pharmaceutical composition which includes a sugar and a Krebs cycle intermediate or salt thereof, or a precursor of a Krebs cycle intermediate. Krebs cycle intermediates include citric acid, aconitic acid, isocitric acid, α-ketoglutaric, succinic acid, fumaric acid, malic acid, oxaloacetic acid, and mixtures thereof. Precursors of Krebs cycle intermediates are compounds which, upon administration to a subject, are converted by the body to form a Krebs cycle intermediate. [0013]
  • The present invention also relates to a method of treating impaired mitochondrial function. The method includes administering a pharmaceutical composition of the present invention to a subject having a disorder involving impaired mitochondrial function under conditions effective to improve mitochondrial function. [0014]
  • The present invention further relates to a method of improving cerebral function in an individual having impaired cerebral metabolism. This method includes administering a pharmaceutical composition of the present invention to a subject having impaired cerebral metabolism under conditions effective to improve cerebral function. [0015]
  • The pharmaceutical compositions of the present invention are particularly desirable for the prophylaxis or treatment of disorders associated with impaired mitochondrial function. Disorders that can be treated include conditions or diseases characterized by a decreased level of oxidative metabolism, such as conditions or diseases of the nervous system, conditions or diseases of other parts of the body (e.g., cardiovascular disorders, musculoskeletal disorders, etc.), and conditions or diseases of the body as a whole. The pharmaceutical composition is particularly desirable for use in treating nervous system disorders that are indicated by symptoms of dementia. Upon administration of the pharmaceutical compositions of the present invention, it is possible to reduce the severity of dementia through enhancing cerebral cellular metabolism (i.e., improving mitochondrial function in cerebellar tissues). Thus, the pharmaceutical compositions are particularly useful as a prophylactic for delaying the onset of dementia or as a treatment for delaying the progression of dementia associated with various nervous system disorders. The pharmaceutical compositions are also useful for ameliorating the clinical manifestations of dementing illnesses by improving the function of the remaining, but often metabolically compromised, cells.[0016]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates the Krebs cycle and the relationship between each of its intermediates. Oxaloacetic acid and an acetyl group (from acetyl-CoA) combine to form citric acid. In the course of the cycle, two of the carbon atoms of citric acid are oxidized completely to carbon dioxide, and oxaloacetic acid is regenerated. This process generates one molecule of ATP, three molecules of NADH, and one molecule of FADH[0017] 2. Ultimately, the reduced cofactors NADH and FADH2 are introduced into an electron-transport mechanism that results in their oxidation, which yields additional molecules of ATP.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to a pharmaceutical composition which includes a sugar in combination with a Krebs cycle intermediate or a precursor of a Krebs cycle intermediate. [0018]
  • Krebs cycle intermediates are the acids or salts of compounds which are utilized during the Krebs cycle. Thus, Krebs cycle intermediates include citric acid, aconitic acid, isocitric acid, α-ketoglutaric acid, succinic acid, fumaric acid, malic acid, oxaloacetic acid, or mixtures thereof. Referring again to FIG. 1, depending upon which Krebs cycle intermediate the pharmaceutical composition of the present invention contains, the pharmaceutical composition will be predicted ultimately to yield differing amounts of ATP. It is believed that a number of disorders involving altered oxidative metabolism include a disruption of the Krebs cycle at or prior to conversion of α-ketoglutaric acid to succinic acid. For such disorders, the pharmaceutic compositions of the present invention preferably contain a Krebs cycle intermediate such as succinic acid, fumaric acid, malic acid, oxaloacetic acid, or mixtures thereof. [0019]
  • Precursors of Krebs cycle intermediates are compounds which upon administration to a subject are converted by the body (i.e., in vivo) into a Krebs cycle intermediate. Generally, mono- and di-alkyl citrates, aconitates, isocitrates, α-ketoglutarates, succinates, fumarates, malates, and oxaloacetates are desirable precursors because the ester bonds are readily broken by the body to yield the Krebs cycle intermediate. Other ester precursors may be developed using known technology for enhancing entry of the precursor molecule into affected cells. For example, U.S. Pat. No. 5,739,117 to Yokoyama, which is hereby incorporated by reference, discloses a variety of glucose ester derivatives which more effectively enter brain cells. One preferred class of precursors of Krebs cycle intermediates are compounds which are converted by the body into oxaloacetic acid or oxaloacetate. Exemplary precursors in this class include 2-keto-4-hydroxypropanol, 2,4-dihydroxybutanol, 2-keto-4-hydroxybutanol, 2,4-dihydroxybutyric acid, 2-keto-4-hydroxybutyric acid, aspartates, as well as the previously identified mono- and di-alkyl oxaloacetates. The amino acid aspartate is converted into oxaloacetic acid by the transamination reaction. [0020]
  • Sugars which are suitable for use with the present invention include monosaccharides, such as glucose, fructose, mannose, and galactose; disaccharides such as sucrose, maltose, and lactose; and polysaccharides (i.e., starches such as amylose) that are digested by the body to form monosaccharides. [0021]
  • The pharmaceutical composition of the present invention can also include an adjuvant for enhancing mitochondrial function (i.e., oxidative metabolism). Suitable adjuvants include vitamins, minerals, antioxidants, and other metabolism-enhancing compounds. B-complex vitamins are preferred for administration as adjuvants because of their involvement with metabolism. Exemplary vitamins which are useful as an adjuvant include thiamin (vitamin B[0022] 1), riboflavin (vitamin B2), niacin (Vitamin B3), pyridoxine derivatives (vitamin B6), and pantothenic acid. Exemplary minerals which are useful as an adjuvant include calcium, magnesium, sodium, potassium, and zinc. Exemplary antioxidants include ascorbic acid, alpha-tocopherol, resveritrol, quercetin, and other flavonoids. Exemplary metabolism-enhancing compounds include L-carnitine and its derivatives, and creatine. Creatine supplementation is described in U.S. Pat. No. 5,767,159 to Hultman, which is hereby incorporated by reference. L-camitine has been found to ameliorate abnormalities associated with AD in a model system (Malow et al., “Cultured Cells as a Screen for Novel Treatments of Alzheimer's Disease,” Arch. Neurol. 46:1201-1203 (1989), which is hereby incorporated by reference).
  • The pharmaceutical composition of the present invention can be administered orally, by anal suppository, parenterally, for example, subcutaneously, intravenously, intramuscularly, intraperitoneally, intrathecally, by interstitial infusion, by intranasal instillation, or by application to mucous membranes, such as that of the nose, throat, and bronchial tubes. They may be administered alone or with suitable pharmaceutically-acceptable vehicles, and can be in solid or liquid form such as tablets, capsules, powders, solutions, suspensions, or emulsions. [0023]
  • The solid unit dosage forms can be of the conventional type, such as an ordinary gelatin type containing the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate and a pharmaceutically acceptable vehicle. Suitable vehicles include lubricants and inert fillers. The above described sugars can also serve as fillers. In another embodiment, these compounds are tableted with conventional tablet bases (i.e., sugars as described above) in combination with binders like acacia, gum tragacanth, cornstarch, or gelatin; disintegrating agents such as cornstarch, potato starch, or alginic acid; a lubricant like stearic acid or magnesium stearate; and sweetening agents such as the above described sugars, saccharine, or aspartame; and flavoring agents such as peppermint oil, oil of wintergreen, or artificial flavorings. [0024]
  • The pharmaceutical compositions of the present invention may also be administered in injectable dosages by solution or suspension of these materials in a physiologically acceptable diluent with a pharmaceutical vehicle. Such vehicles include sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants such as those described above. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous sugar solutions formed with the above-described sugars, and glycols such as polypropylene glycol or polyethylene glycol, are preferred liquid vehicles, particularly for injectable solutions. To maintain sterility and prevent action of microorganisms, antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like may be added to the vehicle. [0025]
  • The pharmaceutical composition of the present invention is useful for augmenting cellular metabolism in subjects (e.g., patients) who suffer from a disorder characterized by abnormally decreased levels of oxidative metabolism. It is believed that administration of the pharmaceutical composition of the present invention enhances mitochondrial function by augmenting operation of the Krebs cycle. Administering sugar to a subject provides a carbon source for producing acetyl groups and administering the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate to a subject increases the concentration of the particular Krebs cycle intermediate at the mitochondrial level. It is believed that this has a priming effect, because a four carbon intermediate is needed in order for the two-carbon derivatives of glucose and other substrates to enter the Krebs cycle. Specifically, the two-carbon acetyl group must combine with the four-carbon oxaloacetate to form citrate in order for the Krebs cycle to continue. Malate is in equilibrium with oxaloacetate, and other Krebs cycle intermediates are readily converted to malate and oxaloacetate. The conversion of succinate and fumarate to malate and oxaloacetate is particularly rapid. Metabolically compromised cells tend to utilize Krebs cycle intermediates for the direct generation of energy. More specifically, they utilize the intermediates to generate electrons which then generate ATP through electron transport. While utilizing the intermediates provides an immediate source of energy, doing so compromises the subsequent activity of the Krebs cycle. Administration of the pharmaceutical compositions of the present invention is believed, therefore, to prime the Krebs cycle so that it again operates efficiently. [0026]
  • Thus, another aspect of the present invention relates to a method of treating a subject having a disorder involving impaired mitochondrial function. Generally, the method includes administering the pharmaceutical composition of the present invention to a subject under conditions effective to improve mitochondrial function. [0027]
  • This method of the present invention is particularly useful for the treatment or prophylaxis of disorders associated with impaired mitochondrial function. Disorders that can be treated according to this method generally include conditions or diseases characterized by a decreased level of oxidative metabolism. The disorders may be caused by genetic factors, environmental factors, or both. More specifically, such disorders include conditions or diseases of the nervous system (e.g., neurodegenerative, psychoses, etc.), conditions or diseases of other parts of the body, and conditions or diseases of the body as a whole. Exemplary conditions or diseases of the nervous system include Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, spinocerebellar ataxias, and psychoses (including depression or schizophrenia) associated with oxidative metabolic abnormalities. Exemplary conditions or disorders of other parts of the body include cardiovascular disorders (e.g., atherosclerotic and cardiovascular diseases including myocardial infarctions, angina, cardiomyopathies, cardiac valvular disorders, and other conditions or disorders causing cardiac failure), musculoskeletal disorders in which oxidative metabolism is abnormal (De Coo et al., A Mitochondrial tRNA(Val) Gene Mutation (G1642A) in a Patient With Mitochondrial Myopathy, Lactic Acidosis, and Stroke-like Episodes,” [0028] Neurol. 50:293-295 (1998), which is hereby incorporated by reference), and other conditions or disorders of non-neural tissues in which oxidative metabolism is abnormal, such as frailty, which is a recognized geriatric syndrome often associated with metabolic alterations (Fayette et al., Eur. J. Clin. Nutrition 52:45-53 (1998), which is hereby incorporated by reference).
  • Many conditions or diseases of the nervous system (e.g., AD and those described above) are characterized by cerebral metabolic insufficiencies, which are manifested as impaired cerebral function such as dementia. Therefore, another aspect of the present invention relates to a method of improving cerebral function in a subject having cerebral metabolic insufficiencies. Generally, a pharmaceutical composition of the present invention is administered to a subject having impaired cerebral metabolism under conditions effective to improve the cerebral cellular metabolism. By improving cerebral cellular metabolism, the subject's cerebral function is improved significantly. [0029]
  • Treatment for nervous system disorders typically involves administration of the pharmaceutical composition of the present invention so that the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate is introduced into brain tissue. To exert its desired therapeutic or prophylactic effects, the sugar and the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate must be transported into the brain cells and subsequently the Krebs cycle intermediate and derivatives of the sugar (e.g., pyruvate, acetate) must be incorporated into the brain cell mitochondria (i.e., where they may be incorporated into the Krebs cycle). [0030]
  • Depending upon how the pharmaceutical composition of the present invention is administered (e.g., oral dosage, intravenous injection, etc.) and the conditions of the patient to be treated, effective administration may require overcoming the cerebrovascular endothelium, also called the blood-brain barrier (“BBB”). The BBB is formed by cerebral endothelial cells under the influence of astroglial cells of the brain (Johansson, “Experimental Models of Altering the Blood Brain Barrier,” [0031] Progress in Brain Research, 91:171-175 (1992); Ermisch, “Peptide Receptors of the Blood-Brain Barrier and Substrate Transport into the Brain,” Progress in Brain Research 91:155-161 (1992), which are hereby incorporated by reference). Briefly, the BBB contains a monolayer of tightly connected microvascular endothelial cells with anionic charges. This layer separates two fluid-containing compartments: the blood plasma and extracellular fluid of the brain parenchyma. One of the main functions of the BBB is to regulate the transfer of components between blood plasma and extracellular fluid. The BBB limits free passage of molecules from the blood to the brain cells. This limited penetration into the CNS is noticeable with large molecules of high polarity such as protein conjugates, enzymes, etc. (Bobo et al., “Convection-enhanced Delivery of Macromolecules in the Brain,” Proc. Natl. Acad. Sci. USA, 91:2076-2080 (1994), which is hereby incorporated by reference).
  • According to a first approach, the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate is administered in a form which more readily crosses the BBB and enters individual brain cells. For example, mono- or di-alkyl esters of Krebs cycle intermediates (e.g., malate esters) are particularly preferred. Without being bound to a particular theory, it is believed that the ester precursors are more lipophilic and, therefore, more likely to cross the BBB. See U.S. Pat. No. 5,739,117 to Yokoyama, which is hereby incorporated by reference. [0032]
  • According to another approach, the BBB is circumvented according to any of a variety of known strategies, for example, intrathecal injections (Ommaya, “Implantable Devices for Chronic Access and Drug Delivery to the Central Nervous System,” [0033] Cancer Drug Delivery, 1(2): 169-179 (1984), which is hereby incorporated by reference), surgical implants (U.S. Pat. No. 5,222,982 to Ommaya, which is hereby incorporated by reference), and interstitial infusion (Bobo et al., “Convection-enhanced Delivery of Macromolecules in the Brain,” Proc. Natl. Acad. Sci. USA, 91:2076-2080 (1994), which is hereby incorporated by reference). Each of these strategies involve delivery of the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate to the central nervous system by direct administration into the cerebrospinal fluid or into the brain parenchyma.
  • According to a third approach, the Krebs cycle intermediate or the precursor of a Krebs cycle intermediate is linked to a molecule which enhances crossing of the BBB. Various BBB crossing enhancers have been identified (e.g., permeabilizer peptides), and others are constantly being identified. [0034]
  • As described above, the pharmaceutical composition of the present invention is useful for treating a subject having a nervous system disorder which involves impaired mitochondrial function. Several nervous system disorders are known to involve deficiencies in neurotransmitter systems. For example, AD is associated with degeneration of cholinergic neurons in the basal forebrain that play a fundamental role in cognitive functions, including memory (Becker et al., “Mechanisms of Cholinesterase Inhibition in Senile Dementia of the Alzheimer Type: Clinical, Pharmacological, and Therapeutic Aspects,” [0035] Drug Dev. Res. 12: 163-195 (1988)). As a result of such degeneration, patients suffering from the disease exhibit a marked reduction in acetylcholine synthesis, choline acetyltransferase activity, acetylcholinesterase activity and choline uptake. There have been several approaches employed to treat AD. These generally include the administration of acetylcholinesterase inhibitors or acetylcholine synthesis, storage or release modulators. Also, since activation of NMDA glutamate receptors has also been implicated in the etiologies of HD, amyotrophic lateral sclerosis, olivopontocerebellar atrophy and AD, use of NMDA glutamate receptor antagonists may be of clinical benefit for patients having these disorders (Woodruff et al., “The Interaction Between MK-801 and Receptors for N-methyl-D-aspartate: Functional Consequences,” Neuropharm. 26:903-909 (1987); Greenamyre et al., “N-methyl-D-aspartate Antagonists in the Treatment of Parkinson's Disease,” Arch. Neurol. 48:977-981 (1991); Giuffra et al., “Glutamatergic Therapy of Huntington's Chorea,” Clin. Neuropharm. 15:148-151 (1992), which are hereby incorporated by reference), as well as for patients suffering from certain neurodegenerative effects of aging (Ferris, S. H. “Therapeutic Strategies in Dementia Disorders” Acta Neurol. Scand. 129(Suppl.):23-26 (1990), which is hereby incorporated by reference). With respect to agents used in the treatment of PD, L-dopa and its derivatives are primary therapeutic agents.
  • For treatment of certain nervous system disorders, therefore, the pharmaceutical composition of the present invention can be administered alone or in combination with a therapeutic agent for the treatment of a nervous system disorder. Suitable therapeutic agents include conventional medications for treating such nervous system disorders. By way of example, for treatment of AD, the pharmaceutical composition can be administered in combination with either an acetylcholinesterase inhibitor, an acetylcholine synthesis, storage or release modulator, an NDMA glutamate receptor antagonist, or combinations thereof. A number of suitable acetylcholinesterase inhibitors, acetylcholine synthesis, storage or release modulators, and NDMA glutamate receptor antagonists are currently known and others are continually being discovered and reported. [0036]
  • As described above, the pharmaceutical composition of the present invention is useful for treating a subject having a cardiovascular disorder which involves impaired mitochondrial function. For treatment of certain cardiovascular disorders, therefore, the pharmaceutical composition of the present invention can be administered alone or in combination with conventional agents for the treatment of cardiovascular disorders. By way of example, the pharmaceutical composition of the present invention can be administered simultaneously with either blood-thinners, cholesterol lowering agents, anti-platelet agents, vasodilators, beta-blockers, angiotensin blockers, digitalis and its derivatives, and combinations thereof. A number of suitable blood-thinners, cholesterol lowering agents, anti-platelet agents, vasodilators, beta-blockers, angiotensin blockers, and digitalis derivatives are currently known and others are continually being discovered and reported. [0037]
  • As described above, the pharmaceutical composition of the present invention is useful for treating a subject having a musculoskeletal disorder which involves impaired mitochondrial function. For treatment of certain musculoskeletal disorders, therefore, the pharmaceutical composition of the present invention can be administered alone or in combination with conventional agents for the treatment of musculoskeletal disorders. [0038]
  • EXAMPLES
  • The following Examples are provided to illustrate embodiments of the present invention but are by no means intended to limit its scope. [0039]
  • Example 1 Treating Alzheimer's Disease with Administration of Supplemental Malic Acid and Glucose
  • Malic acid was administered to seven (7) patients with Alzheimer's Disease in an open study. The longest any patient received malic acid was sixteen weeks. Each of the patients received 15 grams of malic acid per day, which was administered by dissolving the malic acid in unsweetened grape juice, which naturally contains glucose. The addition of the malic acid to the unsweetened grape juice resulted in a sour tasting liquid. [0040]
  • Compliance in ingesting this sour liquid was variable. One patient, excluded from the results described herein, simply refused to ingest the formulation of the malic acid in unsweetened grape juice. The malic acid and glucose were administered simultaneously with “best available therapy,” which included Aricept® (available from Eisai Inc., Teaneck, N.J., and Pfizer Inc., New York, N.Y.) in 6 of the 7 patients ([0041] Patients 1 and 3-7).
  • Cognition was measured by the widely-used and robust Mini-Mental State Examination (“MMSE”) (Folstein et al., “Mini-Mental State: A Practical Method for Grading Cognitive States of Patients for the Clinician,” [0042] J. Psychiat. Res. 12:189-198 (1975), which is hereby incorporated by reference. The MMSE is divided into two sections. The first section requires only vocal responses and tests the patient's orientation, memory, and attention. The second section tests the patient's ability to name, follow verbal and written commands, write a sentence spontaneously, and copy a complex polygon. The maximum score on the first section is 21 and the maximum score on the second section is 9, for a maximum total score of 30. Higher scores on the MMSE indicate better performance. Scores of 28-30 indicate normal intelligence, scores of 23 or below indicate dementia, and scores of 9 or below indicate severe dementia.
  • Patients were tested using the MMSE prior to beginning treatment with the malic acid and glucose supplement and again after cessation of the supplement. Results are shown in Table 1 below. [0043]
    TABLE 1
    Treatment of Alzheimer's Disease Patients with Malic
    Acid and Glucose
    Treatment
    Duration MMSE Score
    Patient (weeks) Before Treatment After Treatment Change
    1 10 9 16 7
    2 12 6 13 7
    3 16 25 29 4
    4 2 24 28 4
    5 12 9 13 4
    6 16 9 18 9
    7 2 20 24 4
  • The net result was an improvement (increase) in MMSE score. The improvement was statistically significant, as analyzed using the paired t-test (P=0.00039, two-tailed). In three patients, the MMSE scores changed dramatically, and for the remaining four patients, MMSE scores showed modest advances. All of the patients were also assessed on a care-giver rating scale of function. While behavioral ratings were more variable than cognitive scores, each of the above patients were described by their caregiver(s) as also improving behaviorally. [0044]
  • Example 2 Treating Alzheimer's Disease with Administration of Supplemental Malic Acid Alone
  • In three patients from Example 1, the nutritional supplement was replaced with capsules containing the same amount of malic acid previously taken in the form dissolved in grape juice. All three patients deteriorated markedly within two weeks. In one of these patients, the MMSE score fell from 17 to 12. Relatives of these patients requested that the patients go back on the original formulation. [0045]
  • These observations indicate the beneficial results were not due primarily to a placebo effect, since both the patients and the health care professional conducting the study expected that the patients would do better on the capsules than on the original formulation. These observations also indicate that the beneficial effect is due to the pharmaceutical composition of the present invention, rather than a Krebs cycle intermediate alone. [0046]
  • Example 3 Treatment of Psychoses with Administration of Supplemental Malic Acid and Glucose
  • Two patients who had been clinically diagnosed with depression were under supervised care with conventional treatment. Each of the patients received 15 grams of malic acid per day, which was administered by dissolving the malic acid in unsweetened grape juice, which naturally contains glucose. [0047]
  • Patient No. 1 [0048]
  • A 58 year old woman with a long history of dysthymia with intermittent depression and withdrawal, and a strong family history with schizophrenia, was on maintenance treatment with a selective serotonin reuptake inhibitor, namely Zoloft (50 mg/day). After two weeks on the malic acid and glucose nutritional supplement, she was happier and more active, claiming she no longer needed any other medication. These added beneficial effects were maintained during the month that she was taking the nutritional supplement, and disappeared within a few days after it was discontinued. [0049]
  • Patient No. 2 [0050]
  • A 60 year old man with a strong family history of depression was on maintenance therapy for recurrent depression with an SSRI (Prozac 40 mg/day). After two weeks on the pharmaceutical composition containing malic acid and glucose, the man felt more calm and less pressured. While taking the pharmaceutical composition, the Prozac was reduced to 20 mg/day without deterioration of function. After stopping administration of the pharmaceutical composition, he again required 40 mg/day Prozac. [0051]
  • Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims. [0052]

Claims (34)

What is claimed:
1. A pharmaceutical composition comprising a sugar, a Krebs cycle intermediate or salt thereof, and resveritrol in a pharmaceutically acceptable vehicle.
2. The pharmaceutical composition according to claim 1, wherein the Krebs cycle intermediate is selected from the group consisting of citric acid, aconitic acid, isocitric acid, α-ketoglutaric, succinic acid, fumaric acid, malic acid, oxaloacetic acid, and mixtures thereof.
3. The pharmaceutical composition according to claim 1, wherein the sugar is selected from the group consisting of a monosaccharide, disaccharide, polysaccharide, and mixtures thereof.
4. The pharmaceutical composition according to claim 1 further comprising an adjuvant for enhancing mitochondrial function.
5. The pharmaceutical compositions according to claim 4, wherein the adjuvant is selected from the group consisting of a vitamin, a mineral, an antioxidant other than resveritrol, a metabolism-enhancing compound, and mixtures thereof.
6. The pharmaceutical composition according to claim 5, wherein the metabolism-enhancing compound is selected from the group consisting of creatine, L-carnitine, L-camitine derivatives, and mixtures thereof.
7. The pharmaceutical composition according to claim 5, wherein the vitamin is selected from the group consisting of thiamin, riboflavin, niacin, pyridoxine derivatives, pantothenic acid, and mixtures thereof.
8. The pharmaceutical composition according to claim 5, wherein the mineral is selected from the group consisting of calcium, magnesium, sodium, potassium, zinc, and mixtures thereof.
9. The pharmaceutical composition according to claim 5, wherein the antioxidant is selected from the group consisting of ascorbic acid, alpha-tocopherol, quercetin, and mixtures thereof.
10. A method of treating impaired mitochondrial function comprising:
administering a pharmaceutical composition according to claim 1 to a subject having a disorder involving impaired mitochondrial function under conditions effective to improve mitochondrial function.
11. The method according to claim 10, wherein the Krebs cycle intermediate is selected from the group consisting of citric acid, aconitic acid, isocitric acid, α-ketoglutaric, succinic acid, fumaric acid, malic acid, and oxaloacetic acid, and mixtures thereof.
12. The method according to claim 10 further comprising:
administering an adjuvant for enhancing mitochondrial function.
13. The method according to claim 12, wherein the adjuvant is selected from the group consisting of a vitamin, a mineral, an antioxidant, a metabolism-enhancing compound, and mixtures thereof.
14. The method according to claim 10, wherein the sugar is selected from the group consisting of a monosaccharide, disaccharide, polysaccharide, and mixtures thereof.
15. The method according to claim 10, wherein the pharmaceutical composition is administered to a patient suffering from a nervous system disorder, a cardiovascular disorder, a musculoskeletal disorder, or a disorder of the body as a whole.
16. The method according to claim 15, wherein the nervous system disorder is Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, spinocerebellar ataxia, or a psychosis.
17. The method according to claim 16, wherein the nervous system disorder is Alzheimer's Disease.
18. The method according to claim 17 further comprising:
administering a therapeutic agent selected from a group consisting of an acetylcholinesterase inhibitor, acetylcholine synthesis modulator, acetylcholine storage modulator, acetylcholine release modulator, and NMDA glutamate receptor antagonist.
19. The method according to claim 16, wherein the nervous system disorder is Huntington's Disease.
20. The method according to claim 19 further comprising:
administering an NMDA glutamate receptor antagonist in conjunction with the pharmaceutical composition.
21. The method according to claim 15, wherein the cardiovascular disorder is selected from a group consisting of atherosclerotic cardiovascular disease, cardiomyopathies, cardiac valvular disorders, and disorders causing cardiac failure.
22. The method according to claim 15, wherein the disorder of the body as a whole is frailty.
23. The method according to claim 10, wherein said administering is oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, by intranasal instillation, or by application to mucous membranes.
24. A method of improving cerebral function in a subject having impaired cerebral metabolism comprising:
administering a pharmaceutical composition according to claim 1 to a subject having impaired cerebral metabolism under conditions effective to improve cerebral function.
25. The method according to claim 24, wherein the Krebs cycle intermediate is selected from the group consisting of citric acid, aconitic acid, isocitric acid, α-ketoglutaric, succinic acid, fumaric acid, malic acid, and oxaloacetic acid, and mixtures thereof.
26. The method according to claim 24 further comprising:
administering an adjuvant for enhancing cerebral function.
27. The method according to claim 26, wherein the adjuvant is selected from the group consisting of a vitamin, a mineral, an antioxidant, a metabolism-enhancing compound, and mixtures thereof.
28. The method according to claim 24, wherein the sugar is selected from the group consisting of a monosaccharide, disaccharide, polysaccharide, and mixtures thereof.
29. The method according to claim 24, wherein said administering is oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, by intranasal instillation, or by application to mucous membranes.
30. A pharmaceutical composition consisting essentially of a sugar and a Krebs cycle intermediate or salt thereof in a pharmaceutically acceptable vehicle.
31. The pharmaceutical composition according to claim 30 wherein the sugar is selected from the group consisting of a monosaccharide, disaccharide, polysaccharide, and mixtures thereof.
32. The pharmaceutical composition according to claim 30 wherein the Krebs cycle intermediate is selected from the group consisting of citric acid, aconitic acid, isocitric acid, a-ketoglutaric, succinic acid, fumaric acid, malic acid, and oxaloacetic acid, and mixtures thereof.
33. A method of treating impaired mitochondrial function comprising:
administering a pharmaceutical composition according to claim 30 to a subject having a disorder involving impaired mitochondrial function under conditions effective to improve mitochondrial function.
34. A method of improving cerebral function in a subject having impaired cerebral metabolism comprising:
administering a pharmaceutical composition according to claim 30 to a subject having impaired cerebral metabolism under conditions effective to improve cerebral function.
US10/379,816 1997-10-24 2003-03-04 Nutritional supplement for cerebral metabolic insufficiencies Abandoned US20030176365A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/379,816 US20030176365A1 (en) 1997-10-24 2003-03-04 Nutritional supplement for cerebral metabolic insufficiencies
US11/478,195 US8338382B2 (en) 1997-10-24 2006-06-29 Method of treating impaired mitochondrial function

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6316597P 1997-10-24 1997-10-24
US09/529,091 US6537969B1 (en) 1997-10-24 1998-09-01 Nutritional supplement for cerebral metabolic insufficiencies
US10/379,816 US20030176365A1 (en) 1997-10-24 2003-03-04 Nutritional supplement for cerebral metabolic insufficiencies

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US09529091 Continuation 1998-09-01
US09/529,091 Continuation US6537969B1 (en) 1997-10-24 1998-09-01 Nutritional supplement for cerebral metabolic insufficiencies
PCT/US1998/018120 Continuation WO1999021565A1 (en) 1997-10-24 1998-09-01 Nutritional supplement for cerebral metabolic insufficiencies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/838,128 Continuation-In-Part US20050245612A1 (en) 1997-10-24 2004-05-03 Pharmaceutical compositions for metabolic insufficiencies
US11/478,195 Continuation-In-Part US8338382B2 (en) 1997-10-24 2006-06-29 Method of treating impaired mitochondrial function

Publications (1)

Publication Number Publication Date
US20030176365A1 true US20030176365A1 (en) 2003-09-18

Family

ID=22047375

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/529,091 Expired - Lifetime US6537969B1 (en) 1997-10-24 1998-09-01 Nutritional supplement for cerebral metabolic insufficiencies
US10/379,816 Abandoned US20030176365A1 (en) 1997-10-24 2003-03-04 Nutritional supplement for cerebral metabolic insufficiencies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/529,091 Expired - Lifetime US6537969B1 (en) 1997-10-24 1998-09-01 Nutritional supplement for cerebral metabolic insufficiencies

Country Status (7)

Country Link
US (2) US6537969B1 (en)
EP (1) EP1032403B1 (en)
JP (2) JP2001521002A (en)
AT (1) ATE555780T1 (en)
AU (1) AU760140B2 (en)
CA (1) CA2306875C (en)
WO (1) WO1999021565A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121960A1 (en) * 1999-11-05 2004-06-24 Claudio Soto-Jara Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid like deposits or beta sheet rich pathological precursor thereof
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
US20070015206A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protien comprising a cross-beta structure from a pharmaceutical composition
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
WO2006066244A3 (en) * 2004-12-17 2007-02-22 Alan B Cash Method for extending lifespan and delaying the onset of age-related disease
US20080118529A1 (en) * 2005-07-13 2008-05-22 Gebbink Martijn Frans Ben Gera Adjuvation Through Cross -Beta Structure
US20080241165A1 (en) * 2002-07-09 2008-10-02 Crossbeta Biosciences B.V. Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fiber formation and modulating cross-beta structure-mediated toxicity
US20080267948A1 (en) * 2005-07-13 2008-10-30 Martijn Frans Ben Gerard Gebbink Croos-B Structure Binding Compounds
US20090054351A1 (en) * 2005-07-29 2009-02-26 Tima Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
US20090142377A1 (en) * 2007-11-08 2009-06-04 Crossbeta Biosciences B.V. Immunogenic compositions
US20090155254A1 (en) * 2006-02-16 2009-06-18 Martijn Frans Ben Gerard Gebbink Affinity Regions
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
US20110008376A1 (en) * 2007-11-08 2011-01-13 Martijn Frans Ben Gerard Gebbink Immunogenic compositions capable of activating t-cells
US8399514B2 (en) 2007-02-08 2013-03-19 Biogen Idec Ma Inc. Treatment for multiple sclerosis
US8980832B2 (en) 2003-09-09 2015-03-17 Biogen Idec International Gmbh Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
WO2020077094A1 (en) * 2018-10-11 2020-04-16 Imbria Pharmaceuticals, Inc. Tca cycle intermediates and method of use thereof

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014063A1 (en) * 1994-11-08 1996-05-17 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
US20050245612A1 (en) 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
US20060128671A1 (en) * 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
EP1065931A4 (en) * 1998-04-02 2006-10-11 Avicena Group Inc Compositions containing a combination of a creatine compound and a second agent
DE19853487A1 (en) 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
DE19932197A1 (en) * 1999-07-09 2001-01-18 Neudecker Birgit Topically applied agent with protective and regenerative effect
DE10000577A1 (en) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Treating mitochondrial diseases, e.g. Parkinson's or Alzheimer's disease or retinitis pigmentosa, using fumaric acid derivative, e.g. mono- or dialkyl fumarate, having succinate dehydrogenase stimulating activity
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
DE50213989D1 (en) 2001-01-12 2009-12-24 Biogen Idec Internat Gmbh USE OF FUMIC ACID AMIDES
CA2401383A1 (en) 2001-02-14 2002-08-22 Matthias Rath Compositions of biochemical compounds involved in bioenergy metabolism of cells and method of use
AU2002360696A1 (en) * 2001-12-21 2003-07-30 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
JPWO2003068215A1 (en) * 2002-02-14 2005-06-02 味の素株式会社 Mitochondrial drugs
DE10217314A1 (en) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclic and oxacarboncyclic fumaric acid oligomers
WO2003101402A2 (en) * 2002-06-04 2003-12-11 Avicena Group, Inc. Methods of treating cognitive dysfunction by modulating brain energy metabolism
WO2004012762A2 (en) 2002-08-01 2004-02-12 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
JP2006503847A (en) * 2002-09-27 2006-02-02 チルドレンズ メディカル センター コーポレーション Methods and compositions for the treatment of neurological diseases
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
SE0301947D0 (en) * 2003-07-01 2003-07-01 Gramineer Internat Ab New method and uses
WO2005002567A1 (en) * 2003-07-01 2005-01-13 Essentys Ab Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition
AU2004253579B2 (en) * 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
JP2007527418A (en) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Composition for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
AU2005262472B2 (en) * 2004-06-16 2011-10-27 President And Fellows Of Harvard College Methods and compositions for modulating bax-mediated apoptosis
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
US20060024385A1 (en) * 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
PL369552A1 (en) * 2004-08-12 2006-02-20 Sgp & Sons Ab Pharmaceutical or/and nutrient or/and laboratory preparation for increasing, supporting the functioning of nerve cells and nervous system as well as application of pharmaceutical or/and nutrient or/and laboratory preparation in protection of the functions
RU2007111720A (en) * 2004-08-30 2008-10-10 Канека Корпорейшн (Jp) MITOCHONDRIA ACTIVATORS
ZA200705824B (en) * 2004-12-21 2008-12-31 Critical Care Connections Inc Therapeutic nutrient compositions or combinations comprising a glutamine-containing short chain peptide and an antioxidant
JP2008527002A (en) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ, インコーポレイテッド Novel composition for preventing and treating neurodegenerative disorders and blood coagulation disorders
ZA200709009B (en) * 2005-04-28 2009-01-28 Unilever Plc Peptides having an ace inhibiting effect
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JP2007023010A (en) * 2005-07-19 2007-02-01 Toshiro Azegami Oral composition for adjusting hormone balance after menopause and for preventing and improving parkinson disease
DE102005035917A1 (en) * 2005-07-28 2007-02-01 November Ag Use of isocitrate-/isocitric acid derivatives, in the preparation of medicament to reduce sequences of aging-conditions mutations in cells of an organism
EP2468272A1 (en) * 2006-05-11 2012-06-27 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US8435547B2 (en) * 2006-08-30 2013-05-07 John P. Blass Cream for stimulating mitochondrial activity in the skin
US20090269796A1 (en) * 2007-12-05 2009-10-29 The General Hospital Corporation Methods of detecting and treating myocardial ischemia and myocardial infarction
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
WO2014046603A1 (en) 2012-09-19 2014-03-27 Grespo Ab Compositions for improvement of brain function
US20140243400A1 (en) * 2013-02-28 2014-08-28 University of Alaska Anchorage Compositions comprising citric acid and malic acid and methods and uses thereof
US10238673B2 (en) 2013-03-13 2019-03-26 Genetic Disease Investigators, LLC Methods and compositions for treatment of dry eye and correction of organ dysfunctions
WO2014160423A1 (en) 2013-03-13 2014-10-02 Genetic Disease Investigators, LLC Methods and compositions for correction of organ dysfunction
GB201411937D0 (en) * 2014-07-03 2014-08-20 Medical Res Council Succinate dehydrogenase inhibitors (SDH's)
JP6831558B2 (en) * 2016-08-23 2021-02-17 株式会社Hbcフナト Brain function improving composition
KR102542842B1 (en) * 2016-09-22 2023-06-14 알란 비. 캐쉬 How to relieve the symptoms of PMS
JP6129395B1 (en) * 2016-10-29 2017-05-17 誠一 荒木 Reduced vitamin B2 preparation for recovery and protection of vascular endothelial cells caused by mitochondrial activation
IT201700087359A1 (en) * 2017-07-28 2019-01-28 Professional Dietetics Spa COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION
JP2022504771A (en) * 2018-10-24 2022-01-13 ポンセ デ レオン ヘルス デシグネイテッド アクティビティ カンパニー Nicotinamide riboside composition for the purpose of extending healthy life expectancy
WO2022166847A1 (en) * 2021-02-05 2022-08-11 崔德斌 Composition and use thereof
CN115212195B (en) * 2022-06-17 2024-02-27 重庆医科大学 Application of malic acid in preparation of medicines for preventing and/or treating depression

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089985A (en) * 1974-11-11 1978-05-16 Wolff H Ezra Papaya juice product and process
US4161539A (en) * 1977-04-11 1979-07-17 The Dow Chemical Company Use of malic acid as a ruminant feed additive
US4957922A (en) * 1985-10-24 1990-09-18 Bayer Aktiengesellschaft Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-di-hydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylic acid
US4975217A (en) * 1981-07-20 1990-12-04 Kimberly-Clark Corporation Virucidal composition, the method of use and the product therefor
US5086050A (en) * 1989-05-05 1992-02-04 Asta Pharma Ag Method of treating inflammatory disorders and psoriasis with salts of azelastine
US5185161A (en) * 1984-03-21 1993-02-09 Alcide Corporation Disinfection method and composition therefor
US5188861A (en) * 1990-05-31 1993-02-23 Royal Domaine Inc. Process for preparing a dried fruit product
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5531993A (en) * 1993-09-15 1996-07-02 L'oreal Stable acidic oil-in-water type emulsions and compositions containing them
US5591774A (en) * 1986-12-23 1997-01-07 Yu; Ruey J. Method of treating wrinkles using malic acid
US5624922A (en) * 1990-09-10 1997-04-29 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5776460A (en) * 1995-06-07 1998-07-07 Man Ki Park Processed ginseng product with enhanced pharmacological effects
US6001852A (en) * 1996-08-13 1999-12-14 P.N. Gerolymatos S.A. Clioquinol for the treatment of Alzheimer's disease
US6147121A (en) * 1998-04-10 2000-11-14 Societe L'oreal S.A. Skin toning by stimulating collagen synthesis/proliferation of dermal fibroblasts
US20060246155A1 (en) * 1997-10-24 2006-11-02 Blass John P Method of treating impaired mitochondrial function

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963579A (en) 1973-10-17 1976-06-15 Sanraku-Ocean Co., Ltd. Microbiological process for the production of pepstatins
DE2502735B2 (en) * 1975-01-23 1978-11-23 J. Pfrimmer & Co, 8520 Erlangen Use of glycerophosphates
GB8617482D0 (en) * 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
JP2736103B2 (en) 1988-03-01 1998-04-02 ヴァルター・ビルクマイヤー Pharmaceutical for treating Parkinson's syndrome and method for producing the same
AT397201B (en) 1988-06-03 1994-02-25 Birkmayer Joerg Ddr USE OF THE ENZYME COFACTOR NADPH IN THE PRODUCTION OF A MEDICINAL PRODUCT
GB9215746D0 (en) 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
JP3645580B2 (en) 1993-10-22 2005-05-11 株式会社フジモト・ブラザーズ Brain metabolism improving agent containing glucose ester derivative
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
DE69615181T2 (en) * 1995-06-07 2002-04-25 Cheil Je Dang Co MACHINED GINSENG WITH REINFORCED PHARMACOLOGICAL EFFECT

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089985A (en) * 1974-11-11 1978-05-16 Wolff H Ezra Papaya juice product and process
US4161539A (en) * 1977-04-11 1979-07-17 The Dow Chemical Company Use of malic acid as a ruminant feed additive
US4975217A (en) * 1981-07-20 1990-12-04 Kimberly-Clark Corporation Virucidal composition, the method of use and the product therefor
US5185161A (en) * 1984-03-21 1993-02-09 Alcide Corporation Disinfection method and composition therefor
US4957922A (en) * 1985-10-24 1990-09-18 Bayer Aktiengesellschaft Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-di-hydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylic acid
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5591774A (en) * 1986-12-23 1997-01-07 Yu; Ruey J. Method of treating wrinkles using malic acid
US5086050A (en) * 1989-05-05 1992-02-04 Asta Pharma Ag Method of treating inflammatory disorders and psoriasis with salts of azelastine
US5188861A (en) * 1990-05-31 1993-02-23 Royal Domaine Inc. Process for preparing a dried fruit product
US5624922A (en) * 1990-09-10 1997-04-29 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5531993A (en) * 1993-09-15 1996-07-02 L'oreal Stable acidic oil-in-water type emulsions and compositions containing them
US5776460A (en) * 1995-06-07 1998-07-07 Man Ki Park Processed ginseng product with enhanced pharmacological effects
US6001852A (en) * 1996-08-13 1999-12-14 P.N. Gerolymatos S.A. Clioquinol for the treatment of Alzheimer's disease
US20060246155A1 (en) * 1997-10-24 2006-11-02 Blass John P Method of treating impaired mitochondrial function
US6147121A (en) * 1998-04-10 2000-11-14 Societe L'oreal S.A. Skin toning by stimulating collagen synthesis/proliferation of dermal fibroblasts
US20060252702A1 (en) * 2004-05-03 2006-11-09 Blass John P Method of improving cerebral function

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060069058A1 (en) * 1999-11-05 2006-03-30 Axonyx, Inc. Beta-sheet breaker peptide analogs that inhibit beta-pleated sheet formation in amyloid beta-peptide
US20040121960A1 (en) * 1999-11-05 2004-06-24 Claudio Soto-Jara Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid like deposits or beta sheet rich pathological precursor thereof
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
US8158585B2 (en) 2002-07-09 2012-04-17 Crossbeta Biosciences B.V. Cross-β structure comprising amyloid-binding proteins and methods for detection of the cross-β structure, for modulating cross-β structures fiber formation and modulating cross-β structure-mediated toxicity
US20080241165A1 (en) * 2002-07-09 2008-10-02 Crossbeta Biosciences B.V. Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fiber formation and modulating cross-beta structure-mediated toxicity
US8980832B2 (en) 2003-09-09 2015-03-17 Biogen Idec International Gmbh Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
US10016385B2 (en) * 2004-12-17 2018-07-10 Alan B. Cash Method for extending lifespan delaying the onset of age-related disease
AU2005316295B2 (en) * 2004-12-17 2012-03-22 Alan B. Cash Method for extending lifespan and delaying the onset of age-related disease
WO2006066244A3 (en) * 2004-12-17 2007-02-22 Alan B Cash Method for extending lifespan and delaying the onset of age-related disease
US20080279786A1 (en) * 2004-12-17 2008-11-13 Cash Alan B Method for Extending Lifespan Delaying the Onset of Age-Related Disease
US11173139B2 (en) 2004-12-17 2021-11-16 Alan B. Cash Method for extending lifespan delaying the onset of age-related disease
US20190008816A1 (en) * 2004-12-17 2019-01-10 Alan B. Cash Method for extending lifespan delaying the onset of age-related disease
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
US20080267948A1 (en) * 2005-07-13 2008-10-30 Martijn Frans Ben Gerard Gebbink Croos-B Structure Binding Compounds
US20080118529A1 (en) * 2005-07-13 2008-05-22 Gebbink Martijn Frans Ben Gera Adjuvation Through Cross -Beta Structure
US20070015206A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protien comprising a cross-beta structure from a pharmaceutical composition
US8067187B2 (en) 2005-07-13 2011-11-29 Crossbeta Biosciences B.V. Cross-β structure binding compounds
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US8580750B2 (en) * 2005-07-29 2013-11-12 Tima Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
US9402849B2 (en) 2005-07-29 2016-08-02 Tima Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
US20090054351A1 (en) * 2005-07-29 2009-02-26 Tima Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
US20090155254A1 (en) * 2006-02-16 2009-06-18 Martijn Frans Ben Gerard Gebbink Affinity Regions
US8399514B2 (en) 2007-02-08 2013-03-19 Biogen Idec Ma Inc. Treatment for multiple sclerosis
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
US20110052564A1 (en) * 2007-11-08 2011-03-03 Martijn Frans Ben Gerard Gebbink Enhancement of immunogenicity of antigens
US20110008376A1 (en) * 2007-11-08 2011-01-13 Martijn Frans Ben Gerard Gebbink Immunogenic compositions capable of activating t-cells
US20090142377A1 (en) * 2007-11-08 2009-06-04 Crossbeta Biosciences B.V. Immunogenic compositions
WO2020077094A1 (en) * 2018-10-11 2020-04-16 Imbria Pharmaceuticals, Inc. Tca cycle intermediates and method of use thereof

Also Published As

Publication number Publication date
AU760140B2 (en) 2003-05-08
CA2306875A1 (en) 1999-05-06
ATE555780T1 (en) 2012-05-15
AU9213998A (en) 1999-05-17
US6537969B1 (en) 2003-03-25
WO1999021565A1 (en) 1999-05-06
EP1032403A1 (en) 2000-09-06
JP2001521002A (en) 2001-11-06
CA2306875C (en) 2011-01-04
JP2010189432A (en) 2010-09-02
EP1032403A4 (en) 2004-03-31
EP1032403B1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
US6537969B1 (en) Nutritional supplement for cerebral metabolic insufficiencies
Tolosa et al. Meige disease: striatal dopaminergic preponderance
US20110300236A9 (en) Method of treating impaired mitochondrial function
US20180177839A1 (en) Modulation of Physiological Processes and Agents Useful for Same
US20080009467A1 (en) Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US20210094900A1 (en) Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US20210077440A1 (en) Dopaminergic mimetics
US20210077453A1 (en) Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
US20040229908A1 (en) Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
EP2624821B1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
Sheard Clinical pharmacology of aggressive behavior
JPH1045582A (en) Medicine containing carnitine derivative for treating early stage patient with alzheimer's disease
US20070225237A1 (en) Methods for the prevention and/or the treatment of glutamate cytotoxicity
Prousky Treating dementia with vitamin B
US11219627B2 (en) Clearance of amyloid beta
JP7298919B2 (en) Composition for promoting myelination
US20220378777A1 (en) Compositions and methods for treating alcohol use disorder or a related condition thereof
Gilbert et al. Tourette’s syndrome
Ronald Steriti Age Associated Mental Impairment

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION